We are excited to announce our $6.08M Product Development award from the Cancer Prevention and Research Institute of Texas (CPRIT)! This will support a crucial phase 1 clinical study of our personalized cancer vaccine immunotherapy for patients with recurrent head and neck cancer. We greatly appreciate the support from CPRIT in advancing critical new cancer treatments like Membrex. Our team, under the leadership of Shaker J. C. Reddy, Periasamy Selvaraj, Michael Coleman, Christopher Pack, and Sampath Ramachandiran, has worked hard over the last several years to reach this milestone and we look forward to what's next for Metaclipse Therapeutics- in Texas! #CPRIT #immunotherapy #clinicaltrials #headandneckcancer
BREAKING NEWS: #CPRIT approved $89 million in grants to advance the state’s fight against cancer, including CPRIT Scholar recruitment awards, evidence-based prevention programs and innovative companies developing new cancer drugs and treatments.? READ: https://ow.ly/uKYY50Ub8sP